2018 Fiscal Year Final Research Report
Molecular characterization of ROCK leukemia between leukemia cells and endothelial cells in CNS leukemia
Project/Area Number |
16K21176
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Hematology
Pediatrics
|
Research Institution | Shimane University |
Principal Investigator |
Onishi Chie 島根大学, 学術研究院医学・看護学系, 助教 (30598115)
|
Project Period (FY) |
2016-04-01 – 2019-03-31
|
Keywords | FLT3-ITD / 白血病 / ROCK / FLT3阻害剤 |
Outline of Final Research Achievements |
FLT3 inhibitor-resistant cells were generated by prolonged dose-escalation exposure to quizartinib and/or gilteritinib in FLT3-ITD+ Ba/F3 cells. Combination of Rho-kinase inhibitor, fasudil and FLT3 inhibitor (quizartinib or gilteritinib) reduced proliferation of FLT3 inhibitor-resistant FLT3-ITD+ Ba/F3 cells compared with the same cells treated with quizartinib or gilteritinib alone.
|
Free Research Field |
血液内科
|
Academic Significance and Societal Importance of the Research Achievements |
近年、FLT3阻害剤による白血病細胞の耐性化が問題視されている。今回の私たちの研究から、ROCK阻害剤が、FLT3-ITD陽性白血病細胞におけるFLT3阻害剤抵抗性を克服するの可能性が示唆された。
|